IL-10与可溶性鸡Ⅱ型胶原对实验性关节炎的联合治疗作用  

Combined therapeutic effects of recombinant human IL-10 with soluble chicken typeⅡ collagen on experimental arthritis

作　　者：卢延旭[1] 陈敏珠[2] 路景涛[2] 

机构地区：[1]中国刑事警察学院法医系法医毒理研究室 [2]安徽医科大学临床药理学研究所

出　　处：《中国临床药理学与治疗学》2004年第4期426-429,共4页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的 :考察重组人白细胞介素 10 (rhIL 10 )对可溶性鸡Ⅱ型胶原 (SCCⅡ )治疗大鼠佐剂性关节炎(AA)疗效的影响。方法 :通过测量足肿胀度、体重、胸腺与脾脏系数 ,观察不同部位淋巴细胞ConA增殖反应并检测腹腔巨噬细胞 (PMΦ)与滑膜组织细胞(SMCs)产生IL 1的水平。结果 :与SCCⅡ(0 .0 3mg·kg-1·d-1,ig)或IL 10 (1,2 μg·d-1,sc)单独治疗比较 ,二者联合治疗大鼠AA ,明显改善上述观察指标 ,同时使SCCⅡ的口服耐受诱导期缩短 ,增强了治疗效果。结论 :IL 10能提高SCCⅡ治疗大鼠AA的治疗效果。AIM : To investigate the combined therapeutic effects of recombinant human interleukin-10 (rhIL-10) with soluble chicken collagen typeⅡ (SCCⅡ) on rat adjuvant arthritis(AA). METHODS : The paw swelling, gain in body weight, thymus-and spleen-indices, the lymphocyte proliferative responses induced by ConA and the levels of IL-1 in the peritoneal macrophages (PMΦ) and synovial membrane tissue cells (SMCs) in rats were examined. RESULTS : Compared with SCCⅡ( 0.03 mg·kg -1·d -1, ig) or rhIL-10 (1, 2 μg·d -1, sc) treatment alone, combined treatment of rhIL-10 (1, 2 μg·d -1, sc) with SCCⅡ ( 0.03 mg·kg -1·d -1, ig) significantly improved the above indices, shortened the induced phase of rat oral tolerance (OT) to SCCⅡ, and strengthened the treatment effect. CONCLUSION : rhIL-10 can improve the therapeutic effect of SCCⅡon rat AA.

关 键 词：可溶性鸡Ⅱ型胶原 RHIL-10 联合治疗 佐剂性关节炎 淋巴细胞增殖反应 滑膜组织细胞 腹腔巨嗜细胞 白细胞介素-1 

分 类 号：R979.5[医药卫生—药品] R965[医药卫生—药学]